The Open Philanthropy Project spoke with Dr. Shineman of the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its investigation into Alzheimer’s disease. Conversation topics included the ADDF’s research priorities, challenges and opportunities in the Alzheimer’s disease funding space, and the importance of biomarker development, as well as a number of other issues facing the field.
